Ollin develops best-in-disease ophthalmology therapies, advancing its VEGF/Ang2 bispecific OLN324 toward global Phase 3 in wet AMD and diabetic macular edema.
Products & media
OLN324
Clinical-stage VEGF and Ang2 bispecific antibody entering Phase 3 development for diabetic macular edema and wet age-related macular degeneration.
OLN102
Preclinical TSHR and IGF-1R bispecific antibody for thyroid eye disease and the underlying autoimmune condition Graves' disease.
Team
Jobs
See all jobs for Ollin here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Data current as of June 24, 2026
Leads
Participating Firms
Angels